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Abstract 
 N-methyl-D-aspartate (NMDA) receptors, whose activation requires glycine site 
stimulation, play crucial roles in various physiological and pathological conditions in the 
brain.  We investigated the regulatory roles of potential endogenous glycine site agonists, 
glycine and D-serine, in excitotoxic and ischemic cell death in the cerebral cortex.  
Cytotoxicity of NMDA on rat cerebrocortical slice cultures was potentiated by addition of 
glycine or D-serine.  In contrast, cell death induced by oxygen/glucose deprivation (OGD) 
was not affected by exogenous glycine or D-serine, although blockade of NMDA receptors by 
MK-801 abolished cell death.  In addition, higher concentrations of 2,7-dichlorokynurenic 
acid (DCKA), a competitive glycine site antagonist, were required to suppress OGD-induced 
cell death than those to suppress NMDA cytotoxicity.  We also found that OGD triggered a 
robust increase in extracellular glycine.  A glycine transporter blocker ALX 5407 increased 
the extracellular level of glycine, and the protective effect of DCKA against NMDA 
cytotoxicity was diminished in the presence of ALX 5407.  Sensitivity of NMDA 
cytotoxicity to DCKA was also diminished by L-serine that increased the extracellular level of 
D-serine.  These results indicate that both glycine and D-serine can act as endogenous ligands 
for NMDA receptor glycine site in the cerebral cortex, and that endogenous glycine may 
saturate the glycine site.under ischemic conditions.  The present findings are important for 
the interpretation of the mechanisms of NMDA and OGD cytotoxicity. 
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Introduction 
 Dysregulation of glutamate-mediated excitatory neurotransmission plays a pivotal role in 
various disorders of the central nervous system.  Particularly, over-activation of 
N-methyl-D-aspartate (NMDA) subtype of glutamate receptors is implicated in 
neurodegenerative conditions associated with acute pathological events such as ischemic and 
traumatic brain injury, and also with chronic neurological disorders such as Huntington 
disease (Hardingham and Bading, 2003).  In the case of ischemic stroke, massive release of 
glutamate from neurons and glia results in aberrant stimulation of neuronal NMDA receptors, 
which constitute a major pathway of Ca2+ influx triggering irreversible neuronal injury 
(Arundine and Tymianski, 2003).  Effectiveness of NMDA receptor blockade against injury 
induced by focal ischemia underscores the importance of NMDA receptor over-activation 
(Lipton, 1999), although other Ca2+ influx pathways may prevail under severe ischemic 
conditions (Aarts et al., 2003; Xiong et al., 2004). 
 Agonists acting on the glycine-binding site are required to activate NMDA receptors, 
together with glutamate-binding site agonists such as glutamate and NMDA.  Indeed, 
glycine site antagonists suppress NMDA receptor-mediated neuronal injury in vitro (Patel et 
al., 1990) and in vivo (Foster et al., 1990).  As the name of the binding site stands for, 
glycine was originally identified as an endogenous agonist at the glycine site of NMDA 
receptors (Johnson and Ascher, 1987).  Addition of glycine to dissociated primary neuronal 
cultures exacerbates NMDA cytotoxicity (McNamara and Dingledine, 1990; Patel et al., 
1990).  Conversely, blockade of glycine transporters potentiates NMDA receptor-mediated 
synaptic responses in cortical neurons (Chen et al., 2003; Eulenburg et al., 2005). 
 More recently, the role of D-serine has received much attention (Hashimoto et al., 1992a; 
Martineau et al., 2006).  D-Serine, particularly concentrated in the telencephalon (Hashimoto 
et al., 1995; Schell et al., 1997), can act as a glycine site agonist showing a higher affinity 
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than glycine (Matsui et al., 1995).  Endogenous D-serine has been shown to regulate NMDA 
receptor activity in hippocampal neurons in mixed cell culture and in the cerebellum of 
immature rats (Mothet et al., 2000), and also in the retina (Stevens et al., 2003).  Endogenous 
D-serine is also likely to play an important role in neuropathological conditions.  Shleper et 
al. (2005) have proposed that D-serine is dominant as an endogenous glycine site agonist for 
induction of NMDA cytotoxiciy in hippocampal slice cultures.  Using acute cortical slice 
preparation, we have previously shown that endogenous D-serine participates in acute NMDA 
cytotoxicity and neuronal injury induced by simulated ischemia (Katsuki et al., 2004).  
However, relative contribution of endogenous glycine and D-serine to neuronal damage in the 
cerebral cortex is still unclear. 
 To gain further insight into the roles of endogenous glycine site agonists, we performed 
pharmacological examinations on rat cerebrocortical slice cultures.  Brain slice culture is a 
suitable preparation for investigations of the actions of intercellular diffusible molecules, 
because tissue architecture and spatial relationship of cells in vivo are maintained nearly 
intact.  We evaluated whether alterations of the extracellular levels of glycine and/or D-serine 
could have any impact on cellular damage induced by excitotoxic and ischemic insults. 
 
 
Materials and methods 
Materials 
 NMDA and amino acids were obtained from Nacalai Tesque (Kyoto, Japan).  
2,7-Dichlorokynurenic acid (DCKA) and 
N-[(3R)-([1,1’-biphenyl]-4-yloxy)-3-(4-fluorophenyl)propyl]-N-methylglycine (ALX 5407) 
were obtained from Tocris Cookson (Bristol, UK).  MK-801 was purchased from 
Sigma-Aldrich Chemicals (St. Louis, MO). 
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 Cortical slice cultures 
 Organotypic slice cultures were prepared according to the procedures described 
previously (Fujimoto et al., 2004; Shirakawa et al., 2006).  All experimental procedures were 
approved by our institutional animal experimentation committee, and animals were treated in 
accordance with the guidelines of the U.S. National Institutes of Health regarding the care and 
use of animals for experimental procedures.  Briefly, coronal brain slices of 300 μm 
thickness of each hemisphere were obtained from 2 or 3 day-old Wistar rats, and six 
cerebrocortical slices (or twelve slices, for determination of ischemia-induced amino acid 
release) were transferred onto a Millicell-CM insert membrane (30 mm in diameter; Millipore, 
Bedford, MA, USA) in six-well plates.  Culture medium, consisting of 50% minimal 
essential medium/HEPES (GIBCO, Invitrogen Japan, Tokyo, Japan), 25% Hanks’ balanced 
salt solution (GIBCO) and 25% heat-inactivated horse serum (GIBCO) supplemented with 6.5 
mg/ml glucose and 2 mM glutamine, 100 U/ml penicillin G potassium and 100 μg/ml 
streptomycin sulfate (GIBCO), was supplied at 0.7 ml/well.  Culture medium was replaced 
with fresh medium on the next day of culture preparation, and thereafter, every two days.  
Slices were cultured in a humidified atmosphere of 5% CO2 and 95% air at 34 °C. 
 
Drug treatment and simulated ischemia 
 From 9 or 10 days in vitro (DIV), cultures were maintained for 24 h in 0.7 ml of 
serum-free medium consisting of 75% minimal essential medium/HEPES and 25% Hanks’ 
balanced salt solution supplemented with 6.5 mg/ml glucose, 2 mM glutamine, 100 U/ml 
penicillin G potassium and 100 μg/ml streptomycin sulfate.  Then, slices were treated with 
NMDA (10 or 15 μM) for 24 h in 0.7 ml of serum-free medium containing 5 μg/ml propidium 
iodide (PI).  DCKA (1-10 μM) and amino acids (100-1000 μM) were concomitantly applied 
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with NMDA for 24 h.  ALX 5407 (30 μM) was applied 24 h prior to NMDA, and was also 
present during NMDA treatment. 
 For simulated ischemia, we performed oxygen/glucose deprivation (OGD; Fujimoto et al., 
2004).  From 9 or 10 DIV, cultures were maintained for 24 h in 0.7 ml of serum-free medium.  
At 10 or 11 DIV, slices were pre-incubated for 1 h in 0.7 ml of oxygenated Ringer’s buffer 
composed of 124 mM NaCl, 4.9 mM KCl, 2 mM CaCl2, 1.2 mM KH2PO4, 25.6 mM NaHCO3, 
1.3 mM MgSO4 and 10 mM D-glucose.  Then slices were subjected to ischemic treatment for 
20, 30 or 60 min by submersion into 1.4 ml of deoxygenated glucose-free Ringer’s buffer in a 
humidified atmosphere of 5% CO2 and 1% O2.  After OGD treatment, slices were returned 
to wells containing 0.7 ml of oxygenated serum-free medium containing 5 μg/ml PI and 
maintained for 24 h.  MK-801 (10 μM), glycine (100-1000 μM), D-serine (100-1000 μM) 
and DCKA (10-100 μM) were applied during OGD treatment. 
 For evaluation of the effects of ALX 5407 (30 μM) and transporter substrates (1 mM) on 
the extracellular levels and tissue contents of amino acids, slices were pre-incubated for 1 h 
with oxygenated Ringer’s buffer and then treated with drugs in Ringer’s buffer for 24 h. 
 
Cell death assay 
 The level of PI uptake into slices was used as a measure of cell death (Fujimoto et al., 
2004).  Slices were observed with an inverted fluorescence microscope with a rhodamine 
filter set.  Fluorescence images were captured through a monochrome chilled CCD camera 
(C5985, Hamamatsu Photonics, Hamamatsu, Japan), and stored images were analyzed with 
NIH image 1.62 software.  The average signal intensity in an area of 180 × 180 μm2 within 
the parietal cortex was obtained as the fluorescence value of each slice.  Slice cultures 
treated with 100 μM NMDA for 24 h were used to determine the degree of the standard injury 
in each set of experiments.  Fluorescence values were normalized with the intensity of 
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fluorescence in cultures that received standard injury as 100%. 
 As another parameter to evaluate the extent of cell death, lactate dehydrogenase (LDH) 
activity in culture medium was measured with Cytotoxicity Detection LDH kit (Kyokuto 
Pharmaceutical Industrial, Tokyo, Japan) as described (Shirakawa et al., 2006). 
 
Quantification of amino acids 
 Extracellular levels and tissue contents of amino acids were determined by the procedures 
described previously (Hashimoto et al., 1992b).  Tissue-conditioned Ringer’s buffer after 
addition of 5% trichloroacetic acid, or tissues homogenized in 10% trichloroacetic acid, 
underwent extraction with diethyl ether, and the aqueous layer was harvested as samples.  
Amino acids in the samples were derivatized with o-phthaldialdehyde and Boc-L-cysteine, 
and aliquots were analyzed by the HPLC system (Shimadzu, Kyoto, Japan) with a Nova-Pak 
C18 column (Waters, Tokyo, Japan). 
 
Statistics 
 Data are expressed as means ± S.E.M.  Statistical significance of difference was 
evaluated with one-way analysis of variance followed by Student-Newman-Keuls test.  
Probability values less than 5% were considered significant. 
 
 
Results 
Glycine site agonists exacerbate NMDA cytotoxicity 
 As reported previously (Shirakawa et al., 2006), application of NMDA for 24 h caused 
cell death in cerebrocortical slice cultures as reflected by an increase in PI fluorescence.  
NMDA cytotoxicity showed a steep concentration-response relationship: 10 μM NMDA only 
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modestly increased PI fluorescence, whereas 15 μM NMDA caused a robust increase in the 
fluorescence.  Similar results were obtained when the extent of injury was evaluated by the 
amount of LDH released into culture medium (data not shown). 
 When glycine and D-serine at concentrations of 100 - 1000 μM were applied to slice 
cultures concomitantly with 10 μM NMDA, these glycine site agonists significantly enhanced 
NMDA cytotoxicity (Fig. 1A, B).  Although glycine and D-serine are shown to saturate the 
glycine site of NMDA receptors at concentrations in low micromolar range (Matsui et al., 
1995), we used extremely high concentrations of glycine and D-serine to ensure the saturation 
of the glycine site, because these compounds might be readily wiped out from the 
extracellular space by cellular uptake systems.  The effect of D-serine was more prominent 
than that of glycine.  Exogenous glycine at tested concentrations did not affect cell death 
induced by 15 μM NMDA, whereas D-serine (300-1000 μM) was again effective in 
enhancing the cytotoxic effect of NMDA at this concentration (Fig. 1C, D).  These results 
suggest that the glycine site of NMDA receptors in the cerebral cortex is not normally 
saturated by endogenous agonists. 
 
Glycine site agonists do not affect ischemic cell death 
 Slice cultures that received a brief period of OGD treatment exhibited cell death after 24 h 
of post-incubation in normal medium, as described (Fujimoto et al., 2004).  The extent of 
cell death was dependent on the duration of OGD treatment.  Injury induced by 20 min OGD 
was modest, whereas 30 min OGD induced substantial cell death as shown by an increase in 
PI fluorescence.  LDH assay gave similar results (data not shown). 
 A striking difference was observed between OGD-induced cell death and NMDA 
cytotoxicity with respect to the effects of glycine site agonists.  That is, neither glycine nor 
D-serine showed any significant effects on cell death induced by OGD for 20 and 30 min (Fig. 
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2A-D).  MK-801, a non-competitive NMDA receptor antagonist, almost completely 
inhibited the induction of cell death by 30 min OGD, indicating that NMDA receptors indeed 
play a critical role in cell death under these conditions.  These results imply that endogenous 
supplies of glycine agonists reach a saturated level during OGD treatment. 
 
Ischemic cell death is less sensitive to glycine site blockade than NMDA cytotoxicity 
 To add support for the idea that the extracellular levels of endogenous glycine site 
agonists are elevated during OGD conditions, we examined the effect of DCKA.  Because 
DCKA is a competitive antagonist at the glycine site of NMDA receptors (Baron et al., 1990), 
the potency of the effect of this drug on NMDA receptor-mediated events should be 
influenced by the levels of competing glycine site agonists.  As shown in Fig. 3, both 
NMDA cytotoxicity and OGD-induced cell death were inhibited by DCKA in a 
concentration-dependent manner.  Consistent with our assumption, the range of effective 
concentrations of DCKA was different between these two cytotoxic conditions.  Cytotoxicity 
of 15 μM NMDA was significantly attenuated by DCKA at a concentration as low as 1 μM, 
and was completely abolished by 10 μM DCKA (Fig. 3A and C).  In contrast, OGD-induced 
cell death was not affected by 10 μM DCKA, and was significantly inhibited by DCKA at 
concentrations of 30 μM or higher (Fig. 3B and D). 
 
Extracellular levels of glycine and D-serine are elevated during ischemia 
 Next we directly assessed whether OGD was accompanied by increased levels of 
extracellular glycine site agonists.  We analyzed the levels of several amino acids released 
during exposure of slices to deoxygenated glucose-free Ringer’s buffer, with an established 
HPLC method (Hashimoto et al., 1992b).  Consistent with the crucial role of NMDA 
glutamate receptors in OGD-induced cell death, the extracellular concentration of glutamate 
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was markedly increased by OGD treatment for 30 min (Table 1).  Notably, a robust increase 
of extracellular glycine was also observed in response to 30 min OGD.  Prolongation of the 
OGD period to 60 min resulted in a further increase in extracellular glycine.  In addition, the 
extracellular concentration of D-serine increased significantly in response to 60 min OGD, but 
the absolute change in D-serine concentration was much smaller than that in glycine 
concentration.  We also observed that other small neutral amino acids, including L-alanine, 
L-serine and L-threonine, were released at significant amounts during 60 min of OGD 
treatment (Table 1). 
 
Manipulations that increase extracellular glycine or D-serine affect NMDA cytotoxicity 
Because the extracellular levels of endogenous glycine site agonists were considered to 
be insufficient to saturate the glycine site of NMDA receptors during NMDA treatment (Fig. 
1), experimental manipulations that affect the release and/or uptake of these agonists may 
influence the cytotoxic consequences of NMDA.  To address this issue, we carried out two 
sets of experiments. 
First, we examined the effect of blockade of glycine transporters.  Of two known 
glycine transporters, GLYT1 is widely distributed in the central nervous system and is 
involved in glial uptake of glycine (Cubelos et al., 2005; Eulenburg et al., 2005).  ALX 5407, 
a potent and selective GLYT1 blocker, showed no significant effect on the cytotoxicity of 
NMDA applied at 15 μM (Fig. 4A) or 10 μM (data not shown).  However, when combined 
with DCKA, ALX 5407 caused a rightward shift of the concentration dependency of the effect 
of DCKA.  That is, the protective effect of 3 μM DCKA against 15 μM NMDA was largely 
abrogated in the presence of 30 μM ALX 5407 (Fig. 4A).  Measurement of amino acid levels 
by HPLC revealed that 24 h treatment of slice cultures with 30 μM ALX 5407 caused a 
marked increase in extracellular glycine, whereas the concentration of extracellular D-serine 
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exhibited no significant change (Table 2). 
Second, we sought to determine the influence of a selective increase in extracellular 
D-serine.  Unlike in the case of glycine, specific transporters for D-serine uptake have not 
been described.  Instead, transporters for small neutral amino acids, such as Asc-1 and ASCT, 
recognize D-serine as a substrate, and several reports have suggested that these transporters 
are involved in regulation of the extracellular levels of D-serine (Fukasawa et al., 2000; 
Ribeiro et al., 2002; Helboe et al., 2003).  Accordingly, we examined the effects of excess 
amount of amino acid transporter substrates, because ASCT transporters can mediate 
heteroexchange of amino acids between extracellular and intracellular compartments 
(Zerangue and Kavanaugh, 1996), and also because small neutral amino acids have been 
reported to enhance D-serine release from cultured astrocytes (Ribeiro et al., 2002).  
Application of 1 mM L-serine for 24 h resulted in a significant increase in extracellular 
D-serine, but had no significant effect on extracellular glycine (Table 2).  L-Alanine (1 mM) 
also caused a significant but small increase in extracellular D-serine, whereas L-threonine (1 
mM) showed no significant effect.  Neither L-alanine nor L-threonine affected the level of 
extracellular glycine.  Measurement of tissue contents of free amino acids showed that the 
effects of exogenous amino acids on extracellular D-serine coincided with the effects on 
intracellular levels of D-serine.  That is, L-serine caused a robust increase in intracellular 
D-serine, whereas L-alanine caused a significant but small increase, and L-threonine had no 
significant effect (Table 3). 
The influences of exogenous L-alanine, L-serine and L-threonine on NMDA cytotoxicity 
were examined.  These amino acids alone at 1 mM had no significant effect on NMDA 
cytotoxicity.  However, L-serine caused a rightward shift of the concentration dependency of 
the protective effect of DCKA against NMDA cytotoxicity, in a similar manner to ALX 5407.  
L-Alanine and L-threonine did not modulate the effect of DCKA (Fig. 4B-D). 
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Discussion 
 The present study was aimed to obtain insights into the roles of glycine and D-serine in the 
regulation of excitotoxic events associated with neurodegenerative conditions.  Results 
suggest that the changes in the extracellular levels of endogenous glycine and D-serine can 
influence the extent of cellular damage in the cerebral cortex.  Although in this study we did 
not discriminate the types of cells damaged by NMDA and OGD, previous studies have 
demonstrated that neurons are vulnerable to these insults (Shirakawa et al., 2002; Hassen et 
al., 2004; Wilkins et al., 2006). 
 NMDA cytotoxicity was markedly enhanced by exogenous addition of glycine and 
D-serine, which suggests that the glycine site of NMDA receptors in the cerebral cortex is not 
saturated by endogenous glycine site agonists.  This is consistent with a previous study 
showing that NMDA receptor-mediated synaptic transmission in the prefrontal cortex can be 
enhanced by exogenous glycine and D-serine (Chen et al., 2003).  D-Serine was found to be 
more potent than glycine in enhancing NMDA cytotoxicity.  This difference may be in part 
attributable to the fact that added glycine can be cleared efficiently from the extracellular 
space by high-affinity glycine transporters, whereas the extracellular level of D-serine remains 
elevated because of the lack of specific transporters for this amino acid.  In addition, 
D-serine exhibits a higher affinity to the glycine site of NMDA receptors than glycine (Matsui 
et al., 1995), which may also contribute to the potent effect of exogenous D-serine.  In our 
previous study using acute cortical slice preparation, addition of glycine and D-serine had no 
effect on NMDA-induced cellular damage (Katsuki et al., 2004).  In that study, cell death 
was evaluated at 6 h after 30 min exposure to NMDA.  Thus, assessment of cell death at 
longer term (24 h exposure to NMDA) in the present study may have improved detection of 
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the influences of altered levels of the extracellular glycine site agonists. 
 In contrast to NMDA cytotoxicity, ischemic cell death induced by OGD was not affected 
by exogenous glycine or D-serine, although OGD-induced cell death was definitely dependent 
on NMDA receptor activation as shown by the protective effect of MK-801.  A reasonable 
explanation is that the extracellular levels of glycine site agonists are elevated under ischemic 
conditions, which lead to saturation of the glycine site.  Supporting this notion, the results of 
the experiments using DCKA showed that much higher concentrations of a competitive 
glycine site antagonist were required to inhibit OGD-induced cell death, than those to inhibit 
NMDA cytotoxicity.  It should be cautioned that several variables such as pH and the redox 
status might also be involved in the alterations of the pharmacological profile of NMDA 
receptors under ischemic conditions (Herin and Aizenman, 2004).  Therefore, the low 
sensitivity to DCKA of OGD-induced cell death might not be totally attributable to the 
increase in glycine site agonists.  Despite these caveats, however, we indeed detected a 
significant increase in extracellular glycine and D-serine during OGD, by an HPLC analysis. 
 The increase in the extracellular levels of glycine in response to OGD treatment was much 
more robust than that of D-serine.  Similar results have been reported in the rabbit cerebral 
cortex during transient focal ischemia in vivo (Lo et al., 1998).  We observed a significant 
increase in extracellular glycine concentration immediately after 30 min OGD.  Because cell 
death was not yet induced at this time point (data not shown), leakage of glycine from 
damaged cells is unlikely to contribute to this initial increase in extracellular glycine.  The 
pathways for glycine efflux into the extracellular space are unclear, but GLYT1 is a potential 
candidate.  GLYT1 mediates symport of glycine with Na+ and Cl−, and the direction of 
transport may be reversed by alterations of transmembrane ion gradients and membrane 
potential that should occur under ischemic conditions (Eulenburg et al., 2005).  Other 
candidates for glycine efflux pathway are several families of amino acid transporters with 
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broad specificity that transport glycine as well as other amino acids (Hyde et al., 2003).  For 
example, Asc-1 is a Na+-independent exchanger of small neutral amino acids including 
glycine, L-alanine, L-serine and L-threonine, which can mediate both influx and efflux of these 
amino acids.  The fact that the extracellular levels of L-alanine, L-serine and L-threonine 
were also elevated in response to a prolonged period of OGD is consistent with possible 
involvement of amino acid transporters with a broad spectrum. 
 We could selectively increase the extracellular levels of endogenous glycine and D-serine, 
by application of ALX 5407 and L-serine, respectively.  That is, a selective GLYT1 blocker 
ALX 5407 induced a significant increase in extracellular glycine but had no effect on 
extracellular D-serine.  On the other hand, L-serine increased the extracellular level of 
D-serine but not of glycine.  Because we could only analyze amino acids escaped from the 
tissues into Ringer’s buffer, the obtained values of concentrations may not faithfully reflect 
the levels of these amino acids in narrow extracellular space within the cortical tissue.  
However, both ALX 5407 and L-serine caused a rightward shift of the concentration 
dependency of the protective effect of DCKA against NMDA cytotoxicity, indicating that 
these agents increased the concentrations of endogenous glycine site agonists in the vicinity 
of NMDA receptors. 
 Because neutral amino acid transporters have been implicated in the efflux pathway for 
D-serine (Ribeiro et al., 2002), we expected that application of excess amounts of the 
substrates for these amino acid transporters increase the extracellular level of D-serine by 
countertransport (Zerangue and Kacanaugh, 1996).  Contrary to the expectation, L-threonine, 
a potent inducer of D-serine efflux from cultured astrocytes (Ribeiro et al., 2002), did not 
affect the extracellular level of D-serine, although a large amount of L-threonine itself was 
incorporated into the slices as reflected by the increase in tissue content.  L-Serine and 
L-alanine indeed caused a significant increase in extracellular D-serine, but this effect is likely 
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to result from accelerated synthesis of D-serine.  L-Serine is a direct precursor of D-serine 
whose production is catalyzed by serine racemase (Wolosker et al., 1999), and in the present 
study, L-serine treatment induced a robust increase in the tissue content of L-serine and 
D-serine.  We observed that L-alanine treatment also resulted in an increase in tissue D-serine 
pool.  The mechanisms of L-alanine-induced increase in D-serine are unclear, although 
L-alanine and L-serine share pyruvate as a common metabolic product.  Interestingly, 
changes in the extracellular concentrations of D-serine after treatment with L-alanine, L-serine 
and L-threonine, roughly paralleled those in the tissue levels of D-serine and L-serine.  These 
results suggest that the availability of the precursor L-serine is an important determinant of the 
extracellular level of D-serine.  In sharp contrast, the extracellular level of glycine did not 
fluctuate significantly, despite neutral amino acids, particularly L-serine, caused a remarkable 
increase in the tissue content of glycine (Tables 2 and 3).  This result suggests tight 
regulation of glycine levels by glycine transporters. 
 Our results do not suggest that amino acid transporters are the major routes for D-serine 
release.  As an alternative route, exocytotic release machinery has been proposed to mediate 
D-serine release from cultured cortical astrocytes (Mothet et al., 2005).  On the other hand, 
recent evidence has demonstrated that cortical neurons can synthesize D-serine, and neuronal 
release of D-serine may not involve exocytotic pathway (Kartvelishvily et al., 2006).  Hence, 
multiple routes can mediate D-serine efflux into the extracellular space, and their relative 
contributions may be varied depending on different physiological and pathological conditions. 
 
 
Conclusion 
 The present study showed that both glycine and D-serine could act as endogenous ligands 
for NMDA receptor glycine site and influence excitotoxic consequences in the cerebral cortex.  
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Particularly, massive release of glycine may lead to saturation of the glycine site of NMDA 
receptors and drive excitotoxic events under ischemic conditions.  These findings provide 
important information for the interpretation of the results of various in vitro experiments on 
NMDA cytotoxicity and ischemic neuronal death.  Identification of cellular origins and 
efflux pathways for glycine and D-serine requires further investigations. 
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Figure Legends 
Fig. 1. Exogenous glycine and D-serine exacerbate cellular damage induced by NMDA.  
Glycine (A, C) or D-serine (B, D) at indicated concentrations was concomitantly applied with 
10 μM (A, B) or 15 μM (C, D) of NMDA for 24 h.  The extent of cell death at 24 h was 
evaluated by the level of PI fluorescence.  n = 18 slices for all groups.  *** P < 0.001 vs. 
control; # P < 0.05, ## P < 0.01, ### P < 0.001 vs. NMDA alone.  $$, P < 0.01, $$$, P < 
0.001 vs. NMDA plus the corresponding concentration of glycine (columns in panel A or C). 
 
Fig. 2. Exogenous glycine and D-serine do not affect cellular damage induced by OGD.  
(A-D) Slices were treated with deoxygenated glucose-free Ringer’s buffer for 20 min (A, B) 
or 30 min (C, D), and further incubated for 24 h in oxygenated medium.  Glycine (A, C) or 
D-serine (B, D) at indicated concentrations were applied during OGD treatment.  n = 12 - 18 
slices for all groups, except for the groups treated with glycine or D-serine alone (n = 6).  (E) 
MK-801 prevents cellular damage by OGD.  Slices were treated with 10 μM MK-801 in 
deoxygenated glucose-free Ringer’s buffer for 30 min and incubated for further 24 h in 
oxygenated medium.  n = 13 for the group treated with MK-801 alone, and n = 30 - 36 for 
all other groups.  The extent of cell death at 24 h was evaluated by the level of PI 
fluorescence.  *** P < 0.001 vs. control; ### P < 0.001 vs. OGD alone. 
 
Fig. 3. Different sensitivity of NMDA cytotoxicity and OGD-induced cell death to DCKA, a 
competitive glycine site antagonist.  (A) Representative images of PI fluorescence of a 
control slice (left), a slice treated with 15 μM NMDA for 24 h (middle) and a slice treated 
with 15 μM NMDA and 10 μM DCKA for 24 h (right).  (B) Representative images of PI 
fluorescence of a control slice (left), a slice incubated for 24 h after 30 min of OGD treatment 
(middle) and a slice incubated for 24 h after 30 min of OGD treatment in the presence of 10 
22 
μM DCKA (right).  Scale bar, 100 μm.  (C) Summary of the effect of DCKA against 
NMDA cytotoxicity.  DCKA at indicated concentrations was concomitantly applied with 15 
μM NMDA for 24 h.  n = 43 - 45.  (D) Summary of the effect of DCKA against 
OGD-induced cell death.  Slices were treated with deoxygenated glucose-free Ringer’s 
buffer for 30 min, and further incubated for 24 h in oxygenated medium.  DCKA at indicated 
concentrations was applied during OGD treatment.  n = 6 for the group treated with DCKA 
alone, and n = 24 - 30 for all other groups.  *** P < 0.001 vs. control; ## P < 0.01, ### P < 
0.001 vs. NMDA or OGD alone. 
 
Fig. 4. Effects of a GLYT1 blocker and amino acid transporter substrates on NMDA 
cytotoxicity.  (A) Slices were treated with 15 μM NMDA and indicated concentrations of 
DCKA for 24 h, in the absence (open columns) or the presence (shaded columns) of 30 μM 
ALX 5407.  ALX 5407 was applied 24 h before and during treatment with NMDA and 
DCKA.  n = 12 for all groups.  (B-D) Slices were treated with 15 μM NMDA and indicated 
concentrations of DCKA for 24 h, in the absence (open columns) or the presence (shaded 
columns) of L-alanine (1 mM; B), L-serine (1 mM; C) and L-threonine (1 mM; D).  n = 12 
for the groups treated with L-alanine, L-serine and L-threonine alone, and n = 17 - 30 for all 
other groups.  The extent of cell death at 24 h was evaluated by the level of PI fluorescence.  
*** P < 0.001 vs. control; # P < 0.05, ## P < 0.01.  ALX 5407 and L-serine caused a 
rightward shift of the concentration dependency of the effect of DCKA against NMDA 
cytotoxicity, whereas L-alanine and L-threonine had no effect. 
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Table 1. OGD-induced changes in the extracellular concentrations of amino acids (in ?M)
Treatment L-Glutamate Glycine  D-Serine  L-Alanine L-Serine  L-Threonine
Control (7) 0.62 ? 0.11 2.35 ? 0.78 0.38 ? 0.17 9.13 ? 0.85 4.46 ? 0.82 22.22 ? 2.69 
30 min OGD (7) 10.04 ? 2.11*** 8.55 ? 1.06*** 0.55 ? 0.19 16.23 ? 0.80*** 5.86 ? 0.92 26.18 ? 2.86 
Control (4) 1.70 ? 0.40 4.49 ? 1.09 0.65 ? 0.17 7.62 ? 1.66 6.18 ? 0.87 20.60 ? 4.17 
60 min OGD (4) 60.93 ? 6.27*** 67.46 ? 11.32** 1.37 ? 0.18* 28.23 ? 3.57** 17.00 ? 1.55*** 39.59 ? 8.12* 
Cortical slice cultures were treated with deoxygenated glucose-free Ringer’s buffer for 30 or 60 min.  Then the buffer was harvested, and amino 
acid levels in the buffer were determined.  The number of samples for each condition is given in parentheses.  * P < 0.05, ** P < 0.01, *** P < 
0.001 vs. control. 
Table 2. Effects of a GLYT1 blocker and ASCT transporter substrates on the extracellular concentrations of amino acids (in ?M)
Treatment  L-Glutamate Glycine   D-Serine  L-Alanine L-Serine  L-Threonine
Control (6)  0.50 ? 0.04 2.84 ? 0.27 1.27 ? 0.07 8.47 ? 1.22 14.22 ? 2.01 19.32 ? 2.40 
30 ?M ALX 5407 (5) 0.73 ? 0.21 27.47 ? 2.90*** 1.48 ? 0.07 14.42 ? 2.26 19.82 ? 0.66 46.47 ? 10.46* 
1 mM L-alanine (3)  0.76 ? 0.03 2.07 ? 0.03 1.68 ? 0.04* 25.20 ? 0.44 16.98 ? 0.72 22.77 ? 0.64 
1 mM L-serine (3)  0.81 ? 0.03 2.58 ? 0.12 3.12 ? 0.05*** 10.70 ? 0.64 Not measurable 24.95 ? 1.08 
1 mM L-threonine (3) 0.71 ? 0.04 2.35 ? 0.50 1.40 ? 0.12  9.18 ? 0.99 14.03 ? 1.40 Not measurable 
Cortical slice cultures were treated with respective drugs in Ringer’s buffer for 24 h.  Then the buffer was harvested, and amino acid levels were 
determined.  The number of samples for each condition is given in parentheses.  * P < 0.05, *** P < 0.001 vs. control. 
Table 3. Effects of ASCT transporter substrates on the tissue levels of amino acids (in nmol/mg protein) 
Treatment  Glycine  D-Serine  L-Alanine L-Serine  L-Threonine
Control (6)  24.43 ? 0.92 0.78 ? 0.08 9.35 ? 0.13 5.30 ? 0.41 8.79 ? 0.36 
1 mM L-alanine (3)  60.05 ? 8.68 2.72 ? 0.41* 24.20 ? 2.43 15.74 ? 1.27 21.55 ? 2.56 
1 mM L-serine (6)  83.42 ? 16.68* 6.80 ? 0.48*** 29.55 ? 6.10 43.37 ? 9.16*** 30.33 ? 5.74 
1 mM L-threonine (3) 35.82 ? 7.79 1.39 ? 0.26 22.72 ? 4.64 6.09 ? 1.01 78.21 ? 17.55 
Cortical slice cultures were treated with respective drugs in Ringer’s buffer for 24 h.  Then the cortical tissue was harvested, and amino acid 
contents were determined.  The number of samples for each condition is given in parentheses.  * P < 0.05, *** P < 0.001 vs. control. 




